Skandinaviska Enskilda Banken (SEB)
VKTX icon

Skandinaviska Enskilda Banken (SEB)’s Viking Therapeutics VKTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,746
Closed -$550K – 892
2025
Q2 		$550K Hold
20,746
– – ﹤0.01% 694
2025
Q1 		$500K Hold
20,746
– – ﹤0.01% 689
2024
Q4 		$824K Sell
20,746
-7,672
-27% -$437K ﹤0.01% 676
2024
Q3 		$1.8M Hold
28,418
– – 0.01% 605
2024
Q2 		$1.5M Hold
28,418
– – 0.01% 599
2024
Q1 		$2.33M Buy
+28,418
New +$1.26M 0.01% 542

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s VKTX Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 20,746 shares — an estimated $550K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in VKTX in Q1 2024 and held it in 6 quarters. The position peaked at $2.33M in Q1 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 20,746 Viking Therapeutics shares in Q3 2025, an estimated $550K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Viking Therapeutics in Q1 2024 and held it in 6 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Viking Therapeutics position peaked at $2.33M in Q1 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.